| Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia T Robak, M Kaźmierczak, I Jarque, V Musteata, J Treliński, N Cooper, ... Blood advances 4 (17), 4136-4146, 2020 | 97 | 2020 |
| Phase II, multiple-dose study of anti-FcRn antibody, rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: interim analysis T Robak, I Jarque, V Musteata, P Kiessling, U Massow, J Higginson, ... Blood 130, 15, 2017 | 16 | 2017 |
| Targeted therapy of chronic myelogenous leukemia: experience of the Institute of Oncology of Moldova V Musteata, I Corcimaru Archives of the Balkan Medical Union 43 (3), 154-155, 2008 | 14 | 2008 |
| GIPAP în Republica Moldova: realizări şi perspective M Vasile, C Ion, S Mircea-Dumitru, M Larisa, R Maria, T Ludmila, C Maria, ... Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 16 (2), 226-228, 2008 | 12 | 2008 |
| A phase 2 study of MT-3724 to evaluate safety, pharmacodynamics and efficacy of MT-3724 for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma DO Persky, V Musteata, M Zodelava, T Perekhrestenko, AE Diaz, ... Blood 134, 5324, 2019 | 7 | 2019 |
| Rozanolixizumab, an anti-FcRn antibody: final results from a phase II, multiple-dose study in patients with primary immune thrombocytopenia T Robak, M Kaźmierczak, I Jarque, V Musteata, J Trelinski, N Cooper, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | 6 | 2019 |
| Actualități în managementul limfoamelor non-Hodgkin: profilul epidemiologic și socioeconomic V Musteață Общественное здоровье, экономика и менеджмент в медицине, 26-32, 2021 | 5 | 2021 |
| S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY T Robak, M Kaźmierczak, I Jarque, V Musteata, J Treliński, N Cooper, ... HemaSphere 3, 379, 2019 | 5 | 2019 |
| Treli nski T Robak, M Kazmierczak, I Jarque, V Musteata J, 0 | 5 | |
| Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma PA Hamlin, V Musteata, SI Park, C Burnett, K Dabovic, T Strack, ... Cancer Research Communications 2 (5), 307-315, 2022 | 3 | 2022 |
| Clinico-laboratory pertinences and management of relapsed and refractory chronic myeloid leukemia V Musteata Journal of BUON 26 (3), 1165-1168, 2021 | 3 | 2021 |
| A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse … AE Diaz Duque, T Perekhrestenko, V Musteata, M Zodelava, TH Guthrie, ... Journal of Clinical Oncology 38 (15_suppl), TPS8074-TPS8074, 2020 | 3 | 2020 |
| Monotherapy activity with the first CD20-targeted immunotoxin, MT-3724, in subjects with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) PA Hamlin, V Musteata, M Zodelava, SI Park, C Burnett, K Dabovic, ... Blood 134, 4098, 2019 | 3 | 2019 |
| Manifestările clinice şi tratamentul limfoamelor Non-Hodgkin mediastinale la adulţi M Robu, I Corcimaru, L Musteaţă, M Popescu, V Gladîş, V Musteaţă, ... Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 48 (3), 366-371, 2015 | 3 | 2015 |
| Epidemiological and Disease Burden Profiles of Leukemias and Malignant Lymphomas: Overview and Trends in the Republic of Moldova and Worldwide V Musteata International Journal of Clinical Medicine 14 (2), 79-95, 2023 | 2 | 2023 |
| Management of elderly patients with chronic myeloproliferative hemopathies V Musteaţă, V Stratan, L Catrinici, L Musteaţă, C Dudnic Moldovan Medical Journal 63 (6), 12-15, 2020 | 2 | 2020 |
| Rezultatele utilizării target-terapiei în tratamentul combinat al tumorilor gastrointestinale stromale (GIST) M Cernat, N Ghidirim, I Mişin, L Antoci, A Donscaia, V Catrinici, ... Arta Medica 60 (3), 49-49, 2016 | 2 | 2016 |
| Manifestările clinice şi tratamentul limfoamelor Non-Hodgkin mediastInale la adulţi R Maria, C Ion, M Larisa, P Maria, G Valentina, M Vasile, B Sanda, ... Universitatea de Stat de MedicInă şi Farmacie „Nicolae Testemiţanu, 0 | 2 | |
| Clinical patterns and complete blood count parameters in the young patients with primary myelofibrosis in the prefibrotic stage N Sghibneva-Bobeico, V Musteaţă, M Robu, L Jalbă, L Musteaţă, ... Revista de Ştiinţe ale Sănătăţii din Moldova 30 (4), 22-26, 2022 | 1 | 2022 |
| Epidemiology and risk factors of warm and cold autoimmune hemolytic anemia M Vasile, TA Khan EDITOR COORDINATOR, 225, 2021 | 1 | 2021 |
Larisa MusteataState University of Medicine and Pharmacy "N. Testemitanu", Institute of OncologyПодтвержден адрес электронной почты в домене usmf.md
